RxDoctor Payments Data

Susan Evans, MD

Neurology · Greenville, NCNPI 1487658415

Payments from drug & device makers

$150,566in general payments, 2019–2025

Across 495 payments — averaging $304.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$34K
  • EMD Serono, Inc.$23K
  • Sanofi$22K
  • AstraZeneca$20K
  • Amgen$18K
  • AbbVie$16K
  • plus $16K from 45 others

What the payments were for

  • Consulting fees$26,93118%
  • Speaking & faculty fees$99,21366%
  • Travel & lodging$11,3508%
  • Food & beverage$12,9349%
  • Education$1380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$150,566 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$308,963
Medicare patients
197
Services billed
11,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab21$815,257
GammakedImmune Globul G/Gly/Iga Avg 4612$663,443
SolirisEculizumab11$548,012
Kesimpta PenOfatumumab34$408,215
VumerityDiroximel Fumarate24$204,577
TysabriNatalizumab17$138,380
Teriflunomide54$119,471
Avonex (4 Pack)Interferon Beta-1a12$99,190
UbrelvyUbrogepant41$43,459
Dalfampridine ErDalfampridine104$40,765
FingolimodFingolimod Hcl19$40,447
QuliptaAtogepant29$37,945
Nurtec OdtRimegepant Sulfate18$35,978
Glatiramer Acetate15$25,324
Aimovig AutoinjectorErenumab-Aooe25$23,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Ocrevus$20$815,25721 claims
AstraZenecaSoliris$20,283$548,01211 claims
BiogenVumerity, Tysabri, Avonex (4 Pack)$12,569$442,14753 claims
AbbVieUbrelvy, Qulipta$16,347$81,40370 claims
PfizerNurtec Odt$14$35,97818 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$178$1,73919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →